[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]

Ho Min Kim; Masataka Ikeda; Miho Okano; Norikatsu Miyoshi; Hajime Hirose; Shinya Yamashita; Ichiro Takemasa; Tsunekazu Mizushima; Hirofumi Yamamoto; Mitsugu Sekimoto; Yuichiro Doki; Masaki Mori

[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy]

Gan To Kagaku Ryoho. 2010 Nov;37(12):2548-50.

[Article in Japanese]

Authors

Ho Min Kim¹, Masataka Ikeda, Miho Okano, Norikatsu Miyoshi, Hajime Hirose, Shinya Yamashita, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori

Affiliation

¹ Dept. of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University.

PMID: 21224635

Abstract

We report a case of 57-year-old woman suffering from advanced sigmoid colon cancer with adrenal and para-aortic lymph node recurrence. Sigmoidectomy was performed for sigmoid colon cancer in January 2002. Pathological staging was Stage II (pT3, pN0, pM0, Cur A). She received a UFT + CPT-11 regimen as preoperative chemotherapy for liver metastasis (S2, S7) from December 2002. A partial liver resection (S2, S7) was performed for liver metastasis in July 2003, and the UFT + CPT-11 was introduced as adjuvant chemotherapy. However, adrenal and para-aortic lymph node recurrence was detected in February 2007, and mFOLFOX6 was performed as preoperative chemotherapy. Right adrenalectomy and para-aortic lymph node dissection was performed in July 2007. mFOLFOX6 as postoperative chemotherapy was done, mFOLFOX6 + bevacizumab was started because of CEA increase. The chemotherapy was performed for 23 courses and temporarily stopped due to adverse reactions, such as peripheral neuropathy (grade 2), general fatigue (grade 1), and nausea (grade 1). She had no recurrence for almost 3 years after a resection of adrenal and para-aortic lymph node metastasis.

Publication types

Case Reports

MeSH terms

Adrenal Gland Neoplasms / secondary*
Adrenal Gland Neoplasms / therapy*
Adrenalectomy
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Aorta
Bevacizumab
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Combined Modality Therapy
Female
Fluorouracil / therapeutic use
Hepatectomy
Humans
Irinotecan
Leucovorin / therapeutic use
Liver Neoplasms / secondary*
Liver Neoplasms / therapy*
Lymphatic Metastasis*
Middle Aged
Neoplasm Recurrence, Local
Organoplatinum Compounds / therapeutic use
Sigmoid Neoplasms / pathology*
Sigmoid Neoplasms / therapy*
Tegafur / administration & dosage
Uracil / administration & dosage

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Phytogenic
Organoplatinum Compounds
Tegafur
Bevacizumab
Uracil
Irinotecan
Leucovorin
Fluorouracil
Camptothecin

Supplementary concepts

1-UFT protocol
Folfox protocol